컴피턴트 세포 시장 규모 및 예측 : 제품별, 용도별, 최종사용자별, 지역별 분석(2023-2030년)

Global Competent Cells Market is valued approximately USD 2.1 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 11.1% over the forecast period 2023-2030. Competent Cells refer to bacterial cells that have been genetically engineered or treated to be capable of taking up foreign DNA molecules from their surrounding environment. These cells possess altered cell wall permeability or contain specific genetic modifications that enable them to efficiently uptake and incorporate exogenous DNA. The Competent Cells market is expanding because of factors such as increasing prevalence of chronic disease and rising funding for studies based on bioscience research. Competent cells are widely used in various genetic engineering techniques, such as transformation and transfection, to introduce recombinant DNA molecules, such as plasmids or viral vectors, into the cell for further manipulation, replication, or expression of desired genes. As a result, the demand of Competent Cells has progressively increased in the international market during the forecast period 2023-2030.

Chronic diseases often require long-term management and treatment, driving the demand for new and more effective therapies. Competent cells are used in drug discovery and development processes to screen for potential drug candidates, validate drug targets, and optimize lead compounds. The growing pipeline of drug candidates targeting chronic diseases fuels the demand for competent cells in pharmaceutical research and development. According to the United Nations report, chronic diseases are anticipated to account for 70% of all global fatalities, while the global disease burden will be 56% by the year 2030. The most significant growth is expected in the African and Eastern Mediterranean regions. Another important factor drives the Competent Cells market is increasing USD 17 million for 48 engineering biology R&D projects. As Bioscience research often contributes to the development of new biotechnological and pharmaceutical products. Competent cells play a crucial role in the production of recombinant proteins, monoclonal antibodies, vaccines, and other biopharmaceuticals. Therefore, as funding for bioscience research grows, so does the demand for competent cells in these industries. In addition, the funding of USD 17.05 million, provided through the UK Research and Innovation (UKRI) Technology Missions Fund and managed by Innovate UK, supports 48 multifaceted projects. These endeavors entail partnerships among private enterprises, academic institutions, and allied organizations spanning different industries. Examples of these projects include groundbreaking efforts such as engineering red blood cells for therapeutic applications, transforming animal stem cells to revolutionize meat production, and refining wound therapy methods to enhance medical treatment outcomes. In addition, the National Institutes of Health expended the majority of its USD 45 billion budget in 2022 for research aimed at improving life and reducing illness and disability. NIH-funded research has resulted in discoveries and innovative therapies, allowing people to live longer, healthier lives and establishing the research foundation that drives innovation. Moreover, increasing development of gene editing technologies and expansion of synthetic biology is anticipated to create a lucrative growth opportunity for the market over the forecast period. However, the high cost of Competent Cells is going to impede overall market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Competent Cells Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising investments from public and private companies and the development of advanced products in the region. In December 2021, Pfizer Inc has inaugurated cutting-edge clinical manufacturing facility in Durham, North Carolina. The facility enhances Pfizer's end-to-end gene therapy capabilities and adds to the company's current presence in North Carolina, where it employs over 3,600 people across multiple facilities. The Durham site is part of a USD 800 million commitment made over the last six years to establish three scalable, cutting-edge gene therapy manufacturing facilities to support Pfizer's ongoing investment in gene therapy research, development, and manufacture. The region's dominant performance is anticipated to propel the overall demand of Competent Cells. Furthermore, Asia Pacific is expected to grow fastest during the forecast period, owing to factors such as rising prevalence of chronic disease in the region. The rising prevalence of chronic diseases drives the pharmaceutical industry's investment in research and development activities, leading to increased demand for competent cells.

Major market player included in this report are:

• Agilent Technologies Inc
• Genescript Biotech Corporation
• Bio-Rad Laboratories Inc
• Merck & Co Inc
• OriGene Technologies, Inc
• New England Biolabs Inc
• Illumina, Inc
• Thermo Fisher Scientific, Inc
• QIAGEN N.V.,
• Zymo Research Corporation

Recent Developments in the Market:

• In April 2024, Agilent Technologies Inc, a global leader in the life sciences, diagnostics, and applied chemical markets, and the University of California San Diego (UC San Diego), one of the world's top public research universities, announced a groundbreaking scientific collaboration to establish the Agilent Centre of Excellence (CoE) in Cellular Intelligence.

Global Competent Cells Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Product, Application, End User, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product

• Chemically Competent Cells
• Electrocompetent Cells

By Application

• Cloning
• Protein Expression
• Other Applications

By End User

• Academic Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

• 1.1.Market Snapshot
• 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1.Competent Cells Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2.Competent Cells Market, by Product, 2020-2030 (USD Billion)
  • 1.2.3.Competent Cells Market, by Application, 2020-2030 (USD Billion)
  • 1.2.4.Competent Cells Market, by End User, 2020-2030 (USD Billion)
• 1.3.Key Trends
• 1.4.Estimation Methodology
• 1.5.Research Assumption

Chapter 2.Global Competent Cells Market Definition and Scope

• 2.1.Objective of the Study
• 2.2.Market Definition & Scope
  • 2.2.1.Industry Evolution
  • 2.2.2.Scope of the Study
• 2.3.Years Considered for the Study
• 2.4.Currency Conversion Rates

Chapter 3.Global Competent Cells Market Dynamics

• 3.1.Competent Cells Market Impact Analysis (2020-2030)
  • 3.1.1.Market Drivers
    • 3.1.1.1.Increasing prevalence of chronic disease
    • 3.1.1.2.Rising funding for studies based on bioscience research
  • 3.1.2.Market Challenges
    • 3.1.2.1.High initial investment for competent cells
    • 3.1.2.2.Lack of skilled professionals
  • 3.1.3.Market Opportunities
    • 3.1.3.1.Increasing development of gene editing technologies
    • 3.1.3.2.Expansion of synthetic biology

Chapter 4.Global Competent Cells Market Industry Analysis

• 4.1.Porter's 5 Force Model
  • 4.1.1.Bargaining Power of Suppliers
  • 4.1.2.Bargaining Power of Buyers
  • 4.1.3.Threat of New Entrants
  • 4.1.4.Threat of Substitutes
  • 4.1.5.Competitive Rivalry
• 4.2.Porter's 5 Force Impact Analysis
• 4.3.PEST Analysis
  • 4.3.1.Political
  • 4.3.2.Economical
  • 4.3.3.Social
  • 4.3.4.Technological
  • 4.3.5.Environmental
  • 4.3.6.Legal
• 4.4.Top investment opportunity
• 4.5.Top winning strategies
• 4.6.COVID-19 Impact Analysis
• 4.7.Disruptive Trends
• 4.8.Industry Expert Perspective
• 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Competent Cells Market, by Product

• 5.1.Market Snapshot
• 5.2.Global Competent Cells Market by Product, Performance - Potential Analysis
• 5.3.Global Competent Cells Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
• 5.4.Competent Cells Market, Sub Segment Analysis
  • 5.4.1.Chemically Competent Cells
  • 5.4.2.Electrocompetent Cells

Chapter 6.Global Competent Cells Market, by Application

• 6.1.Market Snapshot
• 6.2.Global Competent Cells Market by Application, Performance - Potential Analysis
• 6.3.Global Competent Cells Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 6.4.Competent Cells Market, Sub Segment Analysis
  • 6.4.1.Cloning
  • 6.4.2.Protein Expression
  • 6.4.3.Other Applications

Chapter 7.Global Competent Cells Market, by End User

• 7.1.Market Snapshot
• 7.2.Global Competent Cells Market by End User, Performance - Potential Analysis
• 7.3.Global Competent Cells Market Estimates & Forecasts by End User 2020-2030 (USD Billion)
• 7.4.Competent Cells Market, Sub Segment Analysis
  • 7.4.1.Academic Research Institutes
  • 7.4.2.Pharmaceutical & Biotechnology Companies
  • 7.4.3.Contract Research Organizations

Chapter 8.Global Competent Cells Market, Regional Analysis

• 8.1.Top Leading Countries
• 8.2.Top Emerging Countries
• 8.3.Competent Cells Market, Regional Market Snapshot
• 8.4.North America Competent Cells Market
  • 8.4.1.U.S. Competent Cells Market
    • 8.4.1.1.Product breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2.Application breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3.End User breakdown estimates & forecasts, 2020-2030
  • 8.4.2.Canada Competent Cells Market
• 8.5.Europe Competent Cells Market Snapshot
  • 8.5.1.U.K. Competent Cells Market
  • 8.5.2.Germany Competent Cells Market
  • 8.5.3.France Competent Cells Market
  • 8.5.4.Spain Competent Cells Market
  • 8.5.5.Italy Competent Cells Market
  • 8.5.6.Rest of Europe Competent Cells Market
• 8.6.Asia-Pacific Competent Cells Market Snapshot
  • 8.6.1.China Competent Cells Market
  • 8.6.2.India Competent Cells Market
  • 8.6.3.Japan Competent Cells Market
  • 8.6.4.Australia Competent Cells Market
  • 8.6.5.South Korea Competent Cells Market
  • 8.6.6.Rest of Asia Pacific Competent Cells Market
• 8.7.Latin America Competent Cells Market Snapshot
  • 8.7.1.Brazil Competent Cells Market
  • 8.7.2.Mexico Competent Cells Market
• 8.8.Middle East & Africa Competent Cells Market
  • 8.8.1.Saudi Arabia Competent Cells Market
  • 8.8.2.South Africa Competent Cells Market
  • 8.8.3.Rest of Middle East & Africa Competent Cells Market

Chapter 9.Competitive Intelligence

• 9.1.Key Company SWOT Analysis
• 9.2.Top Market Strategies
• 9.3.Company Profiles
  • 9.3.1.Agilent Technologies Inc
    • 9.3.1.1.Key Information
    • 9.3.1.2.Overview
    • 9.3.1.3.Financial (Subject to Data Availability)
    • 9.3.1.4.Product Summary
    • 9.3.1.5.Recent Developments
  • 9.3.2.Genescript Biotech Corporation
  • 9.3.3.Bio-Rad Laboratories Inc
  • 9.3.4.Merck & Co Inc
  • 9.3.5.OriGene Technologies, Inc
  • 9.3.6.New England Biolabs Inc
  • 9.3.7.Illumina, Inc
  • 9.3.8.Thermo Fisher Scientific, Inc
  • 9.3.9.QIAGEN N.V.,
  • 9.3.10.Zymo Research Corporation

Chapter 10.Research Process

• 10.1.Research Process
  • 10.1.1.Data Mining
  • 10.1.2.Analysis
  • 10.1.3.Market Estimation
  • 10.1.4.Validation
  • 10.1.5.Publishing
• 10.2.Research Attributes
• 10.3.Research Assumption